Eli Lilly-backed Abridge expanded its position in clinical trial recruitment and broadened its use cases in life-sciences workflows, backed by an investment through Lilly’s venture arm. The company’s stated goal is to help recruitment teams improve operational efficiency and reach while integrating across trial workflows. The investment underscores Big Pharma’s growing involvement in clinical operations technology, where execution speed and site connectivity can directly influence trial timelines and study feasibility.